Publisher Correction: Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a stage 1 trial

November 10, 2024 medicine

.Nature Medicine, Posted online: 16 Oct 2024 doi:10.1038/ s41591-024-03348-1Publisher Modification: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a period 1 test.